Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Tirzepatide is a dual-action medication that targets both GLP-1 and GIP receptors, which is why clinical trials have shown it producing greater average weight loss than semaglutide alone
By purchasing, you confirm that you are a qualified researcher and that the product will be used solely within a controlled laboratory environment in compliance with all applicable UK laws, regulations, and institutional guidelines.
Methods Data Sources and Searches We searched PubMed (MEDLINE), EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science from database inception to 31 October 2021 to identify eligible RCTs without restriction of language or publication period
Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Companys ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Companys public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR
